Treatment in Elderly Glioblastoma Patients: General Reduction of Standard Therapy Should Be Avoided. Prognostic Value of MGMT Is Questionable

Josef Pichler, Isolde Hoellmüller, Bahil Ghanim, Sabine Spiegl-Kreinecker

Department of Internal Medicine and Neurooncology, Landesnervenklinik, Linz, Austria.
Medical University of Vienna, Vienna, Austria.

DOI: 10.4236/jct.2013.47141                

Abstract

Purpose: Aim of this single center study was to determine whether elderly patients benefit from individualized treatment not excluding full standard therapy. Additionally predictive and prognostic factors influencing outcome in this patient’s population were evaluated. Material and Methods: Between 1997 and 2010, 119 patients equal or older than 60 years were enrolled in this retrospective review. All patients had neuropathology confirmed diagnosis of glioblastoma. Treatment outcome concerning progression free survival was measured by MRI. For evaluation of O6-Methylguanin-DNA-methyltransferase (MGMT) Methylation-specific PCR was used. The log rank test and the Cox proportional hazards model were used to analyze the data. Factors considered in univariate and multivariate analyses included age, gender, Karnofsky performance scale (KPS), extent of resection, treatment with radioand chemotherapy and MGMT status. Survival probabilities were estimated by means of the Kaplan Meier method. Results: Multivariate analysis demonstrated age, KPS and treatment more than surgery as prognostic factors for survival and sex, KPS, type of surgery and standard treatment as independent factors for PFS. MGMT status revealed no difference in survival between the methylated and unmethylated tumours in the whole study population (12.7 and 12.0, respectively). Surgery had an impact on survival with a significant advantage for complete resection. Conclusion: Extent of resection is essential even in elderly patients. Full standard treatment should be offered to elderly GBM patients with good clinical performance, there is no reason to withhold radioor chemotherapy from these patients. MGMT promotor methylation of the tumour is not relevant for treatment decision.

Keywords

Glioblastoma; Elderly Patients; MGMT; Standard Therapy

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, et al., “Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma,” New England Journal of Medicine, Vol. 352, 2005, pp. 987-996. doi:10.1056/NEJMoa043330
[2]	T. L. Gillison and G. S. Chatta, “Cancer Chemotherapy in the Elderly Patient,” Oncology (Williston Park), Vol. 24, No. 1, 2010, pp. 76-85.
[3]	L. Balducci, “Pharmacology of Antineoplastic Medications in Older Cancer Patients,” Oncology (Williston Park), Vol. 23, No. 1, 2009, pp. 78-85.
[4]	A. Hurria and S. M. Lichtman, “Clinical Pharmacology of Cancer Therapies in Older Adults,” British Journal of Cancer, Vol. 98, 2008, pp. 517-522. doi:10.1038/sj.bjc.6604201
[5]	S. M. Lichtman, “Pharmacokinetics and Pharmacodynamics in the Elderly,” Clinical Advances in Hematology & Oncology, Vol. 5, 2007, pp. 181-182.
[6]	D. R. Macdonald, T. L. Cascino, S. C. Schold Jr. and J. G. Cairncross, “Response Criteria for Phase II Studies of Supratentorial Malignant Glioma,” Journal of Clinical Oncology, Vol. 8, 1990, pp. 1277-1280.
[7]	S. Spiegl-Kreinecker, C. Pirker, M. Filipits, D. Lotsch, J. Buchroithner, J. Pichler, et al., “O6-Methylguanine DNA Methyltransferase Protein Expression in Tumor Cells Predicts Outcome of Temozolomide Therapy in Glioblastoma Patients,” Neuro-Oncology, Vol. 12, No. 1, 2010, pp. 28-36. doi:10.1093/neuonc/nop003
[8]	J. G. Scott, J. H. Suh, P. Elson, G. H. Barnett, M. A. Vogelbaum, D. M. Peereboom, et al., “Aggressive Treatment Is Appropriate for Glioblastoma Multiforme Patients 70 Years Old or Older: A Retrospective Review of 206 Cases,” Neuro-Oncology, Vol. 13, No. 4, 2011, pp. 428-436. doi:10. 1093/ne uonc/nor005
[9]	S. E. Combs, J. Wagner, M. Bischof, T. Welzel, F. Wagner, J. Debus, et al., “Postoperative Treatment of Primary Glioblastoma Multiforme with Radiation and Concomitant Temozolomide in Elderly Patients,” International Journal of Radiation Oncology, Biology, Physics, Vol. 70, 2008, pp. 987-992. doi:10.1016/j.ijrobp.2007.07.2368
[10]	A. Malmstrom, B. H. Gronberg, C. Marosi, R. Stupp, D. Frappaz, H. Schultz, et al., “Temozolomide versus Standard 6-Week Radiotherapy versus Hypofractionated Radiotherapy in Patients Older than 60 Years with Glioblastoma: The Nordic Randomised, Phase 3 Trial,” The Lancet Oncology, Vol. 13, No. 9, 2012, pp. 916-926. doi:10.1016/S1470-2045(12)70265-6
[11]	W. Wick, M. Platten, C. Meisner, J. Felsberg, G. Tabatabai, M. Simon, et al., “Temozolomide Chemotherapy Alone versus Radiotherapy Alone for Malignant Astrocytoma in the Elderly: The NOA-08 Randomised, Phase 3 Trial,” The Lancet Oncology, Vol. 13, No. 7, 2012, pp. 707-715. doi:10.1016/S1470-2045(12)70164-X
[12]	J. Gallego Perez-Larraya, F. Ducray, O. Chinot, I. CatryThomas, L. Taillandier, J. S. Guillamo, et al., “Temozolomide in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial,” Journal of Clinical Oncology, Vol. 29, No. 22, 2011, 3050-3055.
[13]	R. Stupp, M. E. Hegi, W. P. Mason, M. J. van den Bent, M. J. Taphoorn, R. C. Janzer, et al., “Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III study: 5-Year Analysis of the EORTC-NCIC Trial,” The Lancet Oncology, Vol. 10, No. 5, 2009, pp. 459-466. doi:10.1016/S1470-2045(09)70025-7
[14]	K. L. Chaichana, K. K. Chaichana, A. Olivi, J. D. Weingart, R. Bennett, H. Brem, et al., “Surgical Outcomes for Older Patients with Glioblastoma Multiforme: Preoperative Factors Associated with Decreased Survival, Clinical Article,” Journal of Neurosurgery, Vol. 114, No. 3, 2011, pp. 587-594. doi:10.3171/2010.8.JNS1081
[15]	A. Mangiola, G. Maira, P. De Bonis, M. Porso, B. Pettorini, G. Sabatino, et al., “Glioblastoma Multiforme in the Elderly: A Therapeutic Challenge,” Journal of NeuroOncology, Vol. 76, No. 2, 2006, pp. 159-163. doi:10.1007/s11060-005-4711-1
[16]	K. Abhinav, K. Aquilina, H. Gbejuade, M. La, K. Hopkins and V. Iyer, “A Pilot Study of Glioblastoma Multiforme in Elderly Patients: Treatments, O-6-Methylguanine-DNA Methyltransferase (MGMT) Methylation Status and Survival,” Clinical Neurology and Neurosurgery, Vol. 115, No. 8, 2013, pp. 1375-1378. doi:10.1016/j.clineuro.2012.12.023
[17]	R. P. Thomas, L. Recht and S. Nagpal, “Advances in the Management of Glioblastoma: The Role of Temozolomide and MGMT Testing,” Clinical Pharmacology: Advances and Applications, Vol. 5, No. 1, 2013, pp. 1-9.
[18]	A. Leibetseder, M. Ackerl, B. Flechl, A. Wohrer, G. Widhalm, K. Dieckmann, et al., “Outcome and Molecular Characteristics of Adolescent and Young Adult Patients with Newly Diagnosed Primary Glioblastoma: A Study of the Society of Austrian Neurooncology (SANO),” NeuroOncology, Vol. 15, No. 1, 2013, pp. 112-121. doi:10.1093/neuonc/nos283